Senate Democrats Reintroduce Federal Cannabis Legalization Bill

Photo by Simon Gagner via Pexels.

Sen. Cory Booker, Majority Leader Chuck Schumer and Sen. Ron Wyden reintroduced the Cannabis Administration and Opportunity Act on July 16, putting a comprehensive federal legalization bill back on the table for the third time since 2022. Neither of the earlier versions made it out of committee, and there's no indication yet that this one is built any differently in terms of political traction.

What makes this reintroduction worth watching isn't just the bill text -- it's the timing. The DEA is simultaneously working through a narrower path that would move cannabis to Schedule III rather than remove it from the Controlled Substances Act altogether. Two federal processes are now running in parallel, aimed at very different destinations, and neither is guaranteed to reach the finish line this year. That leaves the industry, state regulators and everyday consumers watching two tracks at once, trying to figure out which one -- if either -- actually produces a change they can plan around.

What the CAOA Would Actually Do

Photo by RDNE Stock project via Pexels.

The CAOA doesn't tinker with cannabis's placement on the Controlled Substances Act schedules -- it removes the plant from the CSA entirely, which is a fundamentally different move than what the DEA is separately considering. Under the bill, the attorney general would have 180 days after enactment to finalize a rule implementing that de-scheduling, giving federal agencies a hard deadline rather than open-ended discretion.

To fill the regulatory gap that removal would create, the bill sets up a new Center for Cannabis Products inside the FDA, tasked with overseeing manufacturing standards, labeling requirements, distribution channels and retail sales in much the same way the agency already handles tobacco products. States would keep the authority to set their own rules on top of that federal floor -- allowing a state to stay dry, license a handful of dispensaries, or run a wide-open commercial market -- mirroring how alcohol regulation settled out after Prohibition ended.

One provision with an unusually urgent deadline attached: the bill would block a federal recriminalization of hemp-derived THC products currently set to take effect in November. That looming cutoff has been a live concern for the hemp beverage and edibles industry, and CAOA folds a fix for it into the broader legalization package rather than leaving it to a standalone bill.

Taxes, Expungement and Who Cosponsored It

Photo by khezez | خزاز via Pexels.

The tax structure in CAOA is tiered by business size, an approach lawmakers have used before to try to keep smaller cultivators and processors from being squeezed out by well-capitalized multi-state operators. Small and mid-sized producers would face a 5 percent federal excise tax at the outset, climbing to 12.5 percent after five years. Larger cannabis businesses would start at 10 percent and phase up to a ceiling of 25 percent over the same stretch.

On the criminal justice side, the bill requires automatic expungement of low-level federal marijuana convictions within one year of enactment -- no petition process required for those cases. People currently serving federal time for cannabis offenses would get a separate mechanism: the ability to petition courts for resentencing, rather than an automatic release, which leaves judges with discretion over individual cases.

The bill launched with 15 original cosponsors, a lineup that includes Sen. John Fetterman, Sen. Elizabeth Warren, Sen. Kirsten Gillibrand, Sen. Raphael Warnock, Sen. Ed Markey and Sen. Patty Murray, among other Senate Democrats. Notably absent: any Republican cosponsors. That's the same pattern that doomed the bill's prior two introductions, and it's the single clearest signal of how far it's likely to get in the current Congress.

The DEA's Parallel Rescheduling Track

Photo by Michael D Beckwith via Pexels.

While Booker and Schumer were finalizing CAOA's text, the DEA has been moving on a narrower track that started with acting Attorney General Todd Blanche ordering immediate Schedule III rescheduling of state-licensed medical cannabis and FDA-approved cannabinoid drugs back in April. That order didn't touch recreational cannabis sold in adult-use markets, which is a meaningful gap given how much of the industry now operates outside pure medical channels.

The bigger piece of that process is a separate DEA hearing addressing whether to move all cannabis products -- not just the medical and FDA-approved categories -- to Schedule III. That hearing wrapped up on July 15, just a day before CAOA was reintroduced. An administrative law judge overseeing the proceeding has set August 17 as the deadline for final briefs, after which a recommendation is expected to follow.

These two paths aren't complementary -- they're mutually exclusive in an important sense. If CAOA somehow became law, it would remove cannabis from the CSA altogether, which would render the entire DEA rescheduling docket moot regardless of what the administrative law judge recommends. Short of that, a Schedule III move would ease the tax burden that state-legal cannabis businesses currently carry under IRS code 280E, since that provision only applies to Schedule I and II substances. But rescheduling wouldn't legalize cannabis outright, wouldn't touch state law at all, and wouldn't create anything resembling the FDA oversight structure -- the Center for Cannabis Products -- that CAOA proposes.

Reaction and Odds in a GOP Congress

Photo by Erik Mclean via Unsplash.

Maritza Perez Medina of the Drug Policy Alliance framed the reintroduction as a critical opportunity for Congress to finally adopt comprehensive marijuana reform, language that echoes how advocacy groups greeted the bill's earlier versions. On the other side, Republican Rep. Wesley Hunt zeroed in on the tiered tax structure, arguing it functions as a carveout that ultimately favors large, well-funded cannabis companies over the small operators it's ostensibly designed to protect.

The policy landscape underneath this debate has shifted substantially even without federal action. Nearly every state now has some form of medical cannabis law on the books, and 24 states currently regulate adult-use sale and possession -- a footprint that would have seemed unlikely when the first version of this bill was introduced. That expansion is exactly why the current federal-state mismatch has become so unwieldy: state-legal cannabis businesses in those 24-plus states still operate under a federal law that treats their entire industry as illegal, creating the banking access problems and 280E tax complications that CAOA is specifically designed to resolve.

None of that changes the arithmetic in a Republican-controlled Congress, though. The bill faces the same steep odds it faced in 2022 and in its second introduction -- a Democratic-only cosponsor list isn't enough to move legislation through committee, let alone to a floor vote, without at least some Republican buy-in that hasn't materialized in three tries.

Nobody in the reform world is seriously disputing what's in CAOA -- it's a genuinely comprehensive package that bundles tax policy, expungement and FDA oversight into a single bill rather than spreading them across separate fights. The problem was never the substance. It's that the vote count in Congress hasn't shifted in any way that matters since the first version stalled out in 2022, and a third introduction with zero Republican cosponsors doesn't change that math.

The more consequential thing to actually track over the next month is the DEA's rescheduling docket, not this bill. August 17 is a real date on the calendar -- final briefs are due, and an administrative law judge's recommendation should follow relatively soon after. That's a process with actual institutional momentum behind it, unlike a Senate bill waiting on a committee chair who has no reason to schedule a hearing.

Worth remembering, though: even a favorable Schedule III recommendation wouldn't settle the questions CAOA is built to answer. Interstate commerce, full removal from the CSA, a dedicated FDA regulatory framework for retail cannabis products -- none of that gets resolved by a rescheduling decision, however it comes out. So expect this bill, or something very close to it, to get reintroduced again in the next Congress. The underlying gap between federal law and 24 state-regulated markets isn't going away on its own, and until Congress actually changes hands or changes its mind, that gap is what will keep bringing lawmakers back to bills like this one.